SUBCONJUNCTIVAL MITOMYCIN-C INJECTION
Subconjunctival mitomycin-C injection is an adjunctive ophthalmic service that delivers a controlled dose of mitomycin-C beneath the conjunctiva to modulate wound healing. Ophthalmologists use this service to reduce scarring and fibroblast activity in selected eye conditions and procedures. As a result, it supports improved surgical outcomes when excessive tissue response may compromise success.
WHAT THIS SERVICE TREATS
This service targets conditions where abnormal scarring or aggressive healing can limit treatment effectiveness. Surgeons commonly use it in glaucoma-related procedures, pterygium management, and other surgeries that benefit from scar control. Therefore, the ophthalmologist confirms the indication through examination and clinical assessment before recommending treatment.
HOW THE PROCEDURE WORKS
First, the ophthalmologist applies topical anesthesia to ensure comfort. Next, the surgeon injects a carefully measured dose of mitomycin-C beneath the conjunctiva at a targeted site. The medication acts locally to suppress fibroblast proliferation. Consequently, it reduces postoperative scarring while preserving surrounding tissue integrity.
WHO MAY BENEFIT
Subconjunctival mitomycin-C injection may benefit selected patients who require controlled healing response. For example, it may support care in the following situations.
1. Patients undergoing glaucoma filtering procedures
2. Eyes at high risk of postoperative scarring
3. Recurrent pterygium or aggressive conjunctival growths
4. Selected revision surgeries where fibrosis may recur
5. Cases requiring adjunctive wound modulation
RECOVERY AND AFTERCARE
Patients usually resume routine activities shortly after the injection. Mild redness or irritation may occur temporarily. However, prescribed eye drops and follow-up visits help ensure safe recovery. Therefore, adherence to postoperative instructions remains important for optimal results.
SAFETY AND CLINICAL CONSIDERATIONS
When used appropriately, mitomycin-C provides effective scar control. However, careful dosing and proper case selection remain essential. The ophthalmologist evaluates eye surface health, healing capacity, and overall risk before treatment. Ongoing monitoring further supports safe outcomes.